26 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
as biologics that work by using various antibody therapeutic platforms to address specific cancer targets.
Our commercial opportunity could be reduced
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
both of small-molecule drug products, as well as biologics that work by using various antibody therapeutic platforms to address specific cancer targets
8-K
EX-99.1
ZYME
Zymeworks Inc.
2 May 24
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:07pm
development candidates for targets of significant interest,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. “As we prepare … in the antibody-drug conjugate and multispecific antibody space. Our R&D efforts are focused on attractive targets, with the ability to use our
8-K
EX-99.1
ZYME
Zymeworks Inc.
28 Mar 24
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
4:16pm
antibody drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet
8-K
EX-99.1
b5skrz 3gu
6 Mar 24
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
4:13pm
8-K
EX-99.1
720x3j of6evph8uhnw
8 Feb 24
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
4:16pm
8-K
EX-99.1
a7ig28q253adxyvav73i
4 Jan 24
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
6:31am
8-K
EX-10.1
sou9w
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
px6b qefqcv
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
0a59vl2
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
5e1lzr
8 May 23
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:13pm
DEF 14A
c7gkztoodawgx
25 Nov 22
Definitive proxy
6:16am
424B5
1k8z3q7b6i826uad
9 Nov 22
Prospectus supplement for primary offering
4:29pm